Little Movement in Mortgage Rates
Get Alerts FMCC Hot Sheet
Join SI Premium – FREE
MCLEAN, Va., March 20, 2025 (GLOBE NEWSWIRE) -- Freddie Mac (OTCQB: FMCC) today released the results of its Primary Mortgage Market Survey® (PMMS®), showing the 30-year fixed-rate mortgage (FRM) averaged 6.67%.
"The 30-year fixed-rate mortgage has stayed under 7% for nine consecutive weeks, which is helpful for potential buyers and sellers alike,” said Sam Khater, Freddie Mac’s Chief Economist.
News Facts
- The 30-year FRM averaged 6.67% as of March 20, 2025, up slightly from last week when it averaged 6.65%. A year ago at this time, the 30-year FRM averaged 6.87%.
- The 15-year FRM averaged 5.83%, up slightly from last week when it averaged 5.80%. A year ago at this time, the 15-year FRM averaged 6.21%.
The PMMS® is focused on conventional, conforming, fully amortizing home purchase loans for borrowers who put 20% down and have excellent credit. For more information, view our Frequently Asked Questions.
Freddie Mac’s mission is to make home possible for families across the nation. We promote liquidity, stability and affordability in the housing market throughout all economic cycles. Since 1970, we have helped tens of millions of families buy, rent or keep their home. Learn More: Website | Consumers | X | LinkedIn | Facebook | Instagram | YouTube
MEDIA CONTACT:
Angela Waugaman
(703)772-9528
[email protected]
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2fda5aaa-23e8-4af5-824b-bca8c6fcd6d5
Source: Freddie Mac
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Go Global, Go Systemic: China Asset Management Unveils Active Investment Research 5.0
- Halfpricesoft.com Boosts Compatibility for QuickBooks Nonprofit Users with EzCheckPrinting and Virtual Printer Combo
- Efekta Education Appoints AI Veteran Matt Fisher as Chief Technology Officer
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share